Prophylaxis News and Research

RSS

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

HIV prevention: don’t just target serodiscordant couples

A large proportion of heterosexual HIV transmission in sub-Saharan Africa occurs among stable couples who have sexual partners outside of their relationship, shows research published in The Lancet.

8 Feb 2013

Scientists produce monoclonal antibody in tobacco plants that neutralizes rabies viruses

Smoking tobacco might be bad for your health, but a genetically altered version of the plant might provide a relatively inexpensive cure for the deadly rabies virus. In a new research report appearing in The FASEB Journal, scientists produced a monoclonal antibody in transgenic tobacco plants that was shown to neutralize the rabies virus.

2 Feb 2013

AF implicated in sudden cardiac death

People who develop atrial fibrillation are at more than twice the usual risk for sudden cardiac death, reveal US study findings published in JAMA Internal Medicine.

28 Jan 2013

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection

Emergent BioSolutions Inc. today announced the initiation of a Phase 2 clinical trial for NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject.

18 Jan 2013

Link between infections and venous thromboembolism in surgical patients

Despite receiving blood thinners and other clot prevention treatment, some patients still develop potentially lethal blood clots in the first month after their operations anyway, especially if they developed a surgical-site infection while in the hospital, according to results of a study at Johns Hopkins.

16 Jan 2013

Greater selectivity in GI bleeding prophylaxis needed

Researchers have developed a risk-scoring system to identify noncritically ill hospital patients most likely to benefit from prophylactic acid-suppressive medication.

14 Jan 2013

Patients at high-risk for recurrent C. difficile with unnecessary antibiotic use

The impact of antibiotic misuse has far-reaching consequences in healthcare, including reduced efficacy of the drugs, increased prevalence of drug-resistant organisms, and increased risk of deadly infections. A new study featured in the February issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America, found that many patients with Clostridium difficile infection (C. difficile) are prescribed unnecessary antibiotics, increasing their risk of recurrence of the deadly infection.

10 Jan 2013

New scoring system can help clinicians better identify non-ICU patients at risk for GI bleeding

Critically ill patients in hospital intensive care units (ICUs) are routinely prescribed acid-suppressive medications to reduce their risk of developing stress ulcers and gastrointestinal bleeding, both of which can result from being in a stressful environment and from being intubated. Over the years, this routine practice has often been extended to patients outside the ICU, despite a lack of evidence that this population is at significant risk of these complications.

9 Jan 2013

Biogen Idec files rFIXFc BLA with FDA for treatment of hemophilia B

Today Biogen Idec announced the company recently submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B.

7 Jan 2013

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. prescribing information for Pradaxa (dabigatran etexilate mesylate) capsules was updated to include a contraindication related to use in patients with mechanical prosthetic heart valve replacement.

21 Dec 2012

No direct link between dental procedures and prosthetic joint infection

The American Academy of Orthopaedic Surgeons (AAOS), and the American Dental Association (ADA) found that there is insufficient evidence to recommend the routine use of antibiotics for patients with orthopaedic implants to prevent infections prior to having dental procedures because there is no direct evidence that routine dental procedures cause prosthetic joint infections.

19 Dec 2012

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Arthritis translates to “joint inflammation.” The most common form of arthritis is osteoarthritis (OA), which affects 12-15% of North Americans over the age of 60, and will increase in prevalence as our population ages.

19 Dec 2012

FDA approves GSK’s raxibacumab to treat inhalational anthrax

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

14 Dec 2012

BlueGenics aims to discover new drugs from deep sea to combat osteoporosis

Searching for substances from the deep sea to combat osteoporosis and other human common diseases is one of the objectives of the new European research project "BlueGenics" which has received funding of EUR 6 million from the European Commission.

10 Dec 2012

Pressure Right effectively reduces postdischarge nausea and vomiting

In its December 2012 issue, the Outpatient Surgery Magazine's product news section introduces Pressure Right, the longer-acting perioperative, (Rx) antiemetic prophylaxis medical device to its readers.

30 Nov 2012

InSite Vision completes enrollment in BromSite Phase 3 trial for reduction of pain, inflammation

InSite Vision Incorporated today announced that patient enrollment has been completed in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

29 Nov 2012

AVAC report calls for greater access to combination prevention strategies, protection of research funding

AVAC: Global Advocacy for HIV Prevention on Tuesday "released its annual report that calls for an ambitious pace of funding, implementation, and research," VOA News reports, noting the report, titled "Achieving the End: One Year and Counting," "calls for a three-part agenda for ending AIDS: Deliver, Demonstrate, and Develop."